Article Text

Download PDFPDF

Correspondence on ‘Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome’
Free
  1. Tomoyuki Kawada
  1. Hygiene and Public Health, Nippon Medical School, Bunkyo-ku 1138602, Japan
  1. Correspondence to Dr Tomoyuki Kawada, Hygiene and Public Health, Nippon Medical School, Bunkyo-ku 1138602, Japan; kawada{at}nms.ac.jp

Statistics from Altmetric.com

I read with great interest the paper by Scarsi et al.1 The authors examined the effect of colchicine (1 mg/day) in patients with COVID-19 by setting standard of care (hydroxychloroquine, and/or intravenous dexamethasone, and/or lopinavir/ritonavir).1 The adjusted HR (95% CI) of colchicine for mortality was 0.151 (0.062–0.368). In contrast, older age, worse PaO2/FiO2 and higher serum levels of ferritin at entry were no risk factors of mortality. The authors recommended controlled clinical trials to verify efficacy and safety, and I present the following information.

Deftereos et al conducted a prospective, open-label, randomised clinical trial to evaluate the effect of treatment with colchicine (maintenance doses of 0.5 mg two times per day) on cardiac and inflammatory biomarkers and clinical outcomes in patients with COVID-19.2 Mean event-free survival time was significantly longer in the colchicine group, and there was no difference in adverse events between two groups, except for diarrhoea. Perricone et al speculated six mechanisms regarding the effectiveness of colchicine in patients with COVID-19,3 but Deftereos et al reported no significant differences in high-sensitivity cardiac troponin or C reactive protein levels between two groups.2

Brunetti et al also conducted a prospective study and the adjusted ORs (95% CIs) of colchicine for discharge and mortality at the end of the 28 day were 5.0 (1.25–20.1) and 0.20 (0.05–0.80), respectively.4 They speculated that anti-inflammatory and antiviral effects of colchicine might attenuate cytokine storm by severe COVID-19 infection, but there is no clear evidence on the preventive effect of colchicine for cytokine storm.5

In combination with exploring the inflammatory suppression mechanism of colchicine for clinical outcomes in patients with COVID-19, randomised clinical trials should be added to verify the relationship.

References

Footnotes

  • Contributors The author presented the recent information on the association between colchicine and COVID-19.

  • Funding The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles